Scimitar Equity Blog

RegMed Daily, Closing Bell, 2/3/12, stocks rallied on economic optimism, VIX falls and super bowl countdown

Henry McCusker — Fri, 03 Feb 2012 21:10:33 +0000

End of Day, Cause and Effect EOD Commentary: The surprising economic <jobs> data gave stocks a … jolt and was great news. It was beyond all expectations, literally. The numbers were higher than even the highest forecast … more evidence that the economy is gaining strength followed the jobs report. Closing Bell: [...]

RegMed Competitive and Market Intelligence, 2/3/12, stocks soar, if stocks close higher today, they will break an 8 month losing streak on jobs Friday with the pace of growth in the services sector posting a surprising acceleration

Henry McCusker — Fri, 03 Feb 2012 17:55:10 +0000

The 6 W’s: Who, what, where, when, why and what of it … Today’s Gospel: The NASDAQ rallied sharply. The CBOE Volatility Index tumbled below … 17 …. A good sign for … investors versus traders! TGIF – melting some icecubes in russian pouring water … after this week! Mid-Day: The NASDAQ [...]

Athersys (ATHX) Positive Data on MultiStem to treat Stroke

Henry McCusker — Fri, 03 Feb 2012 17:17:26 +0000

Benefits of MultiStem therapy for treating stroke using standard preclinical models The presentation highlights how MultiStem®, a novel allogenic stem cell therapy reduces damage and enhances functional recovery in animals after an ischemic stroke <the role of the spleen in the mechanisms underlying>. Paper was presented at the American Heart Association International Stroke Conference Researchers [...]

Geron (GERN) completes Enrollment in P2 Clinical Trial of Imetelstat in Breast Cancer

Henry McCusker — Fri, 03 Feb 2012 15:34:37 +0000

P2 clinical trial of imetelstat, in combination with paclitaxel, in patients with locally recurrent or metastatic breast cancer (MBC). The P2 trial (B014) was initiated in 12/10, is an open label, multi-center, randomized (1:1) study of the efficacy and safety of treatment with imetelstat plus paclitaxel versus paclitaxel alone in patients with locally recurrent or [...]

RegMed Daily, Pre-Open, 2/3/12, stock futures edged higher, waiting for payrolls data

Henry McCusker — Fri, 03 Feb 2012 12:37:53 +0000

Good morning! Here’s what you … might need to know to start the day. To understand the gyrations in the RegMed universe’s market! It might provide food for thought … and portfolio awareness. Stock futures edged higher on Friday ahead of jobs data that will provide more clues about the strength of the [...]

RegMed Daily, Closing Bell, 2/2/12, stocks narrowly mixed, moving between gains and losses awaiting payroll data, tomorrow

Henry McCusker — Thu, 02 Feb 2012 21:25:03 +0000

End of Day, Cause and Effect EOD Commentary: Stocks tallied limited gains Thursday as the market looked to tomorrow’s employment report as the next indicator of the economic recovery. Economic numbers are showing greater positive trends … compared to last year, but they’re still not as high to mitigate some of the psychological [...]

RegMed Competitive and Market Intelligence, 2/2/12, stocks struggle for direction but, some hold onto small gains

Henry McCusker — Thu, 02 Feb 2012 17:35:16 +0000

The 6 W’s: Who, what, where, when, why and what of it … Today’s Gospel: Traders seem … reluctant to make any … significant … moves ahead of tomorrow’s monthly jobs report, with stocks turning in a … lackluster performance in mid-day trading on Thursday. The major averages have turned mixed on the day after [...]

StemCells (STEM) FDA Authorization for Age-Related Macular Degeneration Clinical Trial

Henry McCusker — Thu, 02 Feb 2012 14:56:03 +0000

STEM initiates a P1/2 clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD). The P1/2 trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll [...]

RegMed Daily, Pre-Open, 2/2/12, stock futures flat and will open flat

Henry McCusker — Thu, 02 Feb 2012 12:29:50 +0000

Good morning! Here’s what you … might need to know to start the day. To understand the gyrations in the RegMed universe’s market! It might provide food for thought … and portfolio awareness. Stock futures were little changed on Thursday ahead of data on weekly jobless claims and testimony by Fed’s Bernanke on [...]

RegMed Daily, Closing Bell, 2/1/12, stocks were off highs ahead of close, slipping in the final hour

Henry McCusker — Wed, 01 Feb 2012 21:25:26 +0000

End of Day, Cause and Effect EOD Commentary: Stocks slipped from their best levels in the final hour of trading Wednesday, but still held some strong gains following a handful of positive global economic news in addition to a report that Greece and its private creditors may only be hours away from a [...]